ES2501592T3 - Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña - Google Patents

Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña Download PDF

Info

Publication number
ES2501592T3
ES2501592T3 ES10014318.9T ES10014318T ES2501592T3 ES 2501592 T3 ES2501592 T3 ES 2501592T3 ES 10014318 T ES10014318 T ES 10014318T ES 2501592 T3 ES2501592 T3 ES 2501592T3
Authority
ES
Spain
Prior art keywords
treatment
stereoisomer
butylphenol
nausea
vomiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES10014318.9T
Other languages
English (en)
Spanish (es)
Inventor
Thomas E. Jenkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SOWOOD HEALTHCARE LLC
Original Assignee
SOWOOD HEALTHCARE LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SOWOOD HEALTHCARE LLC filed Critical SOWOOD HEALTHCARE LLC
Application granted granted Critical
Publication of ES2501592T3 publication Critical patent/ES2501592T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/02Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring monocyclic with no unsaturation outside the aromatic ring
    • C07C39/06Alkylated phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/40Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/42Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/44Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C37/00Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring
    • C07C37/01Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis
    • C07C37/055Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group
    • C07C37/0555Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom of a six-membered aromatic ring by replacing functional groups bound to a six-membered aromatic ring by hydroxy groups, e.g. by hydrolysis the substituted group being bound to oxygen, e.g. ether group being esterified hydroxy groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/24Halogenated derivatives
    • C07C39/26Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms
    • C07C39/27Halogenated derivatives monocyclic monohydroxylic containing halogen bound to ring carbon atoms all halogen atoms being bound to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ES10014318.9T 2007-05-09 2008-05-08 Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña Active ES2501592T3 (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US92829607P 2007-05-09 2007-05-09
US92842907P 2007-05-09 2007-05-09
US92832707P 2007-05-09 2007-05-09
US928429P 2007-05-09
US928327P 2007-05-09
US928296P 2007-05-09

Publications (1)

Publication Number Publication Date
ES2501592T3 true ES2501592T3 (es) 2014-10-02

Family

ID=39798084

Family Applications (1)

Application Number Title Priority Date Filing Date
ES10014318.9T Active ES2501592T3 (es) 2007-05-09 2008-05-08 Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña

Country Status (22)

Country Link
US (4) US8071818B2 (OSRAM)
EP (4) EP2146946B1 (OSRAM)
JP (1) JP5651009B2 (OSRAM)
KR (1) KR20100017436A (OSRAM)
CN (1) CN101715437B (OSRAM)
AT (1) ATE487685T1 (OSRAM)
AU (1) AU2008251482C1 (OSRAM)
BR (1) BRPI0811220A2 (OSRAM)
CA (1) CA2685570A1 (OSRAM)
DE (1) DE602008003431D1 (OSRAM)
DK (2) DK2301908T3 (OSRAM)
ES (1) ES2501592T3 (OSRAM)
HR (1) HRP20140896T1 (OSRAM)
IL (1) IL201795A0 (OSRAM)
MX (1) MX2009012124A (OSRAM)
NZ (1) NZ580752A (OSRAM)
PL (2) PL2146946T3 (OSRAM)
PT (1) PT2146946E (OSRAM)
RU (1) RU2470908C2 (OSRAM)
SI (1) SI2301908T1 (OSRAM)
WO (1) WO2008141097A2 (OSRAM)
ZA (1) ZA201007603B (OSRAM)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2301908T3 (da) 2007-05-09 2014-09-15 Sowood Healthcare Llc (-)-stereoisomer af 2,6-di-sec-butylphenol og analoger dertil til frembringelse af en antiemetisk effekt, behandling af kvalme og opkastning og behandling af migræne
JP5924539B2 (ja) * 2010-08-03 2016-05-25 学校法人 久留米大学 実験用小動物の脳波測定用装置及び脳波測定方法
CN102731265B (zh) * 2012-06-12 2014-12-10 四川百利药业有限责任公司 一种高纯度丙泊酚的制备方法
WO2017205632A1 (en) * 2016-05-27 2017-11-30 The Johns Hopkins University Buccal, sublingual and intranasal delivery of fospropofol
RU2635532C1 (ru) * 2016-09-06 2017-11-13 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики ажитационного синдрома у детей с онкологической патологией
CN115708819A (zh) * 2022-11-24 2023-02-24 中国科学院深圳先进技术研究院 丙泊酚的抗焦虑制药用途及抗焦虑药物制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US237213A (en) 1881-02-01 William j
US2747982A (en) * 1955-05-11 1956-05-29 Dow Chemical Co Method and composition for the control of the growth of vegetation
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4798846A (en) 1974-03-28 1989-01-17 Imperial Chemical Industries Plc Pharmaceutical compositions
SU1525139A1 (ru) * 1987-11-10 1989-11-30 Куйбышевский политехнический институт им.В.В.Куйбышева Способ получени о-втор-бутилфенола
ES2087019B1 (es) * 1994-02-08 1997-03-16 Bobel246 S L Uso de derivados de fenoles 2,4-disubstituidos como inhibidores de la 5-lipoxigenasa.
US5731355A (en) 1994-03-22 1998-03-24 Zeneca Limited Pharmaceutical compositions of propofol and edetate
GB9405593D0 (en) 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions
US6254853B1 (en) 1998-05-08 2001-07-03 Vyrex Corporation Water soluble pro-drugs of propofol
US6204257B1 (en) 1998-08-07 2001-03-20 Universtiy Of Kansas Water soluble prodrugs of hindered alcohols
US6140374A (en) * 1998-10-23 2000-10-31 Abbott Laboratories Propofol composition
AU3000800A (en) 1999-02-18 2000-09-04 Supergen, Inc. Phosphocholine linked prodrug derivatives
US6716452B1 (en) 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6362234B1 (en) 2000-08-15 2002-03-26 Vyrex Corporation Water-soluble prodrugs of propofol for treatment of migrane
US20020099013A1 (en) 2000-11-14 2002-07-25 Thomas Piccariello Active agent delivery systems and methods for protecting and administering active agents
AU2002243204A1 (en) 2000-10-06 2002-06-11 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
ES2325918T3 (es) 2001-12-28 2009-09-24 Eisai Corporation Of North America Formulaciones farmaceuticas de base acuosa de profarmacos de propofol solubles en agua.
EP1485082A4 (en) 2002-02-19 2009-12-30 Xenoport Inc PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
JP5188003B2 (ja) 2002-04-08 2013-04-24 エーザイ インコーポレイテッド プロポフォールの水溶性プロドラッグを含む薬学的組成物およびその投与方法
AU2003273413A1 (en) 2002-10-08 2004-05-04 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
DE20215415U1 (de) 2002-10-08 2004-02-26 Biotechnologie Gesellschaft Mittelhessen Mbh Wasserlösliche Medikamentenvorstufen von Propofol
ZA200504940B (en) 2003-01-28 2006-09-27 Xenoport Inc Amino acid derived prodrugs of propofol, compositions and uses thereof
AU2003901815A0 (en) 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
WO2005023204A2 (en) 2003-09-09 2005-03-17 Xenoport, Inc. Aromatic prodrugs of propofol, compositions and uses thereof
US20070043121A1 (en) * 2003-09-29 2007-02-22 Brown Milton L Discovery of novel soluble crystalline anesthetics
WO2006017351A1 (en) 2004-07-12 2006-02-16 Xenoport, Inc. Prodrugs of propofol, compositions and uses thereof
EP1791521A4 (en) 2004-09-17 2009-10-21 Eisai Corp North America METHODS OF ADMINISTERING PROPOFOL PROMOTERS WITH WATER SOLUBLE
WO2006071995A1 (en) 2004-12-23 2006-07-06 Xenoport, Inc. Serine amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof
DE102005033496A1 (de) * 2005-07-19 2007-01-25 Bayer Healthcare Ag Desinfektionsmittel
WO2007071967A2 (en) 2005-12-19 2007-06-28 The University Of Liverpool Substituted phenol derivatives as analgesics
US7535698B2 (en) 2006-03-07 2009-05-19 Panasonic Corporation Case, portable information equipment using the same and manufacturing method of the case
US7731356B1 (en) * 2006-07-24 2010-06-08 Daniel Ayers Gilbert Hanging eyeglasses
AU2008251484A1 (en) 2007-05-09 2008-11-20 Pharmacofore, Inc. Therapeutic compounds
DK2301908T3 (da) 2007-05-09 2014-09-15 Sowood Healthcare Llc (-)-stereoisomer af 2,6-di-sec-butylphenol og analoger dertil til frembringelse af en antiemetisk effekt, behandling af kvalme og opkastning og behandling af migræne

Also Published As

Publication number Publication date
PL2301908T3 (pl) 2015-02-27
WO2008141097A3 (en) 2008-12-31
ATE487685T1 (de) 2010-11-15
IL201795A0 (en) 2010-06-16
HK1156019A1 (en) 2012-06-01
NZ580752A (en) 2012-03-30
AU2008251482C1 (en) 2014-04-03
AU2008251482A1 (en) 2008-11-20
EP2292577A1 (en) 2011-03-09
EP2146946A2 (en) 2010-01-27
HRP20140896T1 (hr) 2015-01-02
HK1138829A1 (en) 2010-09-03
RU2009145537A (ru) 2011-06-20
KR20100017436A (ko) 2010-02-16
EP2146946B1 (en) 2010-11-10
WO2008141097A2 (en) 2008-11-20
CA2685570A1 (en) 2008-11-20
US8242315B2 (en) 2012-08-14
AU2008251482B2 (en) 2013-09-26
US20130059919A1 (en) 2013-03-07
EP2810927A1 (en) 2014-12-10
EP2301908B8 (en) 2014-09-03
JP5651009B2 (ja) 2015-01-07
DK2301908T3 (da) 2014-09-15
US20120035271A1 (en) 2012-02-09
US20100292346A1 (en) 2010-11-18
PL2146946T3 (pl) 2011-04-29
SI2301908T1 (sl) 2014-10-30
EP2301908B1 (en) 2014-06-25
DE602008003431D1 (de) 2010-12-23
DK2146946T3 (da) 2011-02-14
PT2146946E (pt) 2011-02-14
MX2009012124A (es) 2010-02-18
RU2470908C2 (ru) 2012-12-27
US8071818B2 (en) 2011-12-06
CN101715437B (zh) 2013-06-12
BRPI0811220A2 (pt) 2014-10-29
ZA201007603B (en) 2012-08-29
WO2008141097A9 (en) 2009-04-02
EP2301908A1 (en) 2011-03-30
US8575400B2 (en) 2013-11-05
US8871815B2 (en) 2014-10-28
US20140206773A1 (en) 2014-07-24
JP2010526826A (ja) 2010-08-05
CN101715437A (zh) 2010-05-26

Similar Documents

Publication Publication Date Title
ES2501592T3 (es) Estereoisómero (-) de 2,6-di-sec-butilfenol y análogos del mismo para fomentar el efecto antiemético, tratamiento de náuseas y vómitos y tratamiento de migraña
ES2491140T3 (es) Derivados de flavona enantioméricamente puros para el tratamiento de trastornos proliferativos y procesos para su preparación
PE20131463A1 (es) Piperidino-dihidrotienopirimidinas sustituidas
AR062394A1 (es) Uso de compuestos y derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis
ECSP11011151A (es) Compuestos purina
ES2477940T3 (es) Imidazoles condensados y composiciones que los incluyen para el tratamiento de enfermedades parasitarias tales como por ejemplo malaria
ES2525481T3 (es) Derivados espirocíclicos de ácido tetrónico
DK2152651T3 (da) Terapeutiske forbindelser
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
CO6351777A2 (es) Compuestos de tetraciclina sustituidod con fluor en c7
EA200900924A1 (ru) Циклизованные производные как ингибиторы eg-5
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
PE20061490A1 (es) Derivados de ciclohexanosulfonilo como inhibidores del transportador de glicina glyt1
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
ECSP088781A (es) Derivados de benzimidazol
EA200601845A1 (ru) НОВЫЕ β-АГОНИСТЫ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ЛЕКАРСТВЕННЫХ СРЕДСТВ
ES2544780T3 (es) Metadoxina para su uso como inhibidor de fibrosis hepática
ES2526147T3 (es) Ésteres de metronidazol para el tratamiento de la rosácea
CO6511224A2 (es) Utilización de derivados del indol como activadores de nurr-1 para la aplicación de tratamientos de enfermedades como el parkison
ES2605454T3 (es) Métodos para reducir la neurodegeneración
EA200800125A1 (ru) Фармацевтическая композиция, включающая 1-(3-хлорфенил)-3-алкилпиперазин, для лечения расстройств аппетита
RU2009116125A (ru) Средство для предотвращения отека легких
ES2523901A1 (es) Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica